CanSino Biologics, Inc. Class H (HK:6185) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CanSino Biologics Inc. announced that its supplemental drug application to expand the age range for its Menhycia vaccine has been accepted by China’s National Medical Products Administration. This move is expected to enhance the company’s market presence, as it continues to experience strong revenue growth, with a 39.07% increase in sales of meningococcal vaccines in the first three quarters of 2024 compared to the previous year. Investors may find this development promising as CanSino strengthens its competitive edge in the vaccine industry.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
